MedTrace Logo

QL1706 Plus Chemotherapy +/- Bevacizumab in 1L Treatment of R/mTNBC

NCT06786026 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2025-02-06

No results posted yet for this study

Summary

This study is to evaluate the efficacy and safety of QL1706 plus albumin-bound paclitaxel ± bevacizumab in 1L treatment of r/mTNBC

Conditions

  • TNBC, Triple Negative Breast Cancer

Interventions

DRUG

bevacizumab

bevacizumab

DRUG

QL1706

Bispecific antibody (bsAB) targeting PD-1 and CLTA-4

DRUG

Nab paclitaxel

albumin-bound paclitaxel

Sponsors & Collaborators

  • Fudan University

    lead OTHER

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-10-09
Primary Completion
2025-09-30
Completion
2028-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06786026 on ClinicalTrials.gov